Related Experiment Video

Updated: Jul 11, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

TRAIL in cancer therapy: present and future challenges

Delphine Mérino1, Najoua Lalaoui, Alexandre Morizot

  • 1INSERM, U866, Dijon, F-21079, France.

Expert Opinion on Therapeutic Targets
|October 3, 2007
PubMed

Insights

TNF-related apoptosis-inducing ligand (TRAIL) shows promise for selective cancer cell death induction with minimal toxicity. Further research into TRAIL mechanisms and cancer cell resistance is crucial for effective clinical application.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • TNF-related apoptosis-inducing ligand (TRAIL) identified in 1995.
  • TRAIL selectively induces cancer cell death with low in vivo toxicity.
  • Preclinical evaluations highlight TRAIL's antitumoural potential.

Purpose of the Study:

  • To review recent advances in TRAIL signal transduction.
  • To discuss challenges in TRAIL-based cancer therapy.
  • To understand mechanisms of TRAIL selectivity and cancer cell resistance.

Main Methods:

  • Literature review of TRAIL signal transduction pathways.
  • Analysis of preclinical and clinical TRAIL therapy data.
  • Discussion of cancer cell escape mechanisms from TRAIL-induced apoptosis.

Main Results:

  • TRAIL exhibits selective cancer cell apoptosis induction.
  • Understanding TRAIL mechanisms and cancer resistance is limited.
  • TRAIL's safety profile supports its therapeutic interest.

Conclusions:

  • Further elucidation of TRAIL signaling is needed.
  • Overcoming cancer cell resistance is key for clinical success.
  • TRAIL-based therapies require optimized strategies for effective cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...